National Cancer Institute
Found 1045 results for your search:
Total relevant funding to Chemotherapy for this search:
$289,467,872
Fiscal Year FY 2016
Research Topic [Chemotherapy]
Modify this Search New Search
Close

Modify Search Criteria

Some search criteria may be modified to refine your current search.

Select criteria to modify:

Add or remove search options:

Select criteria above to see additional search options

Cancel
Showing 1 - 50 of 1045 results
Clipboard
Project Title Sorted ascending Project Number Funded Amount
Relevant Funding
Principal
Investigator
Institution
1
(10.) The Gut Microbiome and Responses to Neoadjuvant Chemoradiation in Rectal Cancer Patients 1R21CA205636-01 $168,563 $84,282 CHEN, GRACE UNIVERSITY OF MICHIGAN
2
(PQ #4) Single cell barcoding for studies of study clonal evolution in glioblasto 5R01CA190121-03 $332,000 $109,560 VERHAAK, ROELAND UNIVERSITY OF TX MD ANDERSON CAN CTR
3
(PQ#9)Targeting leaky ryanodine receptor (RyR2) to treat and prevent chemotherapy-associated cognitive dysfunction in patients with breast cancer. 1R01CA206025-01 $655,037 $655,037 GUISE, THERESA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
4
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy 1R21CA205644-01 $167,475 $167,475 WHITESIDE, THERESA UNIVERSITY OF PITTSBURGH AT PITTSBURGH
5
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity 1R01CA205967-01 $390,540 $390,540 LETAI, ANTHONY DANA-FARBER CANCER INST
6
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity 1R01CA205101-01 $406,070 $406,070 SKALA, MELISSA MORGRIDGE INSTITUTE FOR RESEARCH, INC.
7
(PQ9) Characterization and prophylactic treatment of chemotherapy-induced long-term adverse sequelae 1R01CA208634-01 $560,277 $560,277 JURECIC, ROLAND UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
8
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle 7R21CA205437-02 $152,333 $152,333 WANING, DAVID PENNSYLVANIA STATE UNIV HERSHEY MED CTR
9
(PQ9) Novel therapeutic approaches to chemotherapy-induced muscle. 1R21CA205437-01 $51,247 $51,247 WANING, DAVID INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
10
(PQ9) Prevention of Bleomycin-induced Pulmonary Toxicity by Dichloroacetate (DCA) 1R21CA208746-01 $198,485 $198,485 KIM, JUNG-WHAN UNIVERSITY OF TEXAS DALLAS
11
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy 1R01CA205255-01 $577,463 $577,463 SEGAL, ROSALIND DANA-FARBER CANCER INST
12
(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance 5R21CA194679-02 $160,885 $160,885 JAMIESON, CATRIONA UNIVERSITY OF CALIFORNIA SAN DIEGO
13
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLL 5R01CA184922-03 $553,684 $276,842 WU, CATHERINE DANA-FARBER CANCER INST
14
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers 5R01CA184968-03 $509,161 $254,581 SIKIC, BRANIMIR STANFORD UNIVERSITY
15
(PQD5) A novel genetic strategy to predict efficacy of anti-CD20 antibodies 5R01CA185372-03 $321,937 $321,937 RICHARDS, KRISTY CORNELL UNIVERSITY
16
(PQD5) Avatar-directed Treatment for Ovarian Cancer 5R01CA184502-03 $714,297 $714,297 WEROHA, SARAVUT MAYO CLINIC ROCHESTER
17
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling 5R01CA185353-03 $405,890 $405,890 SHARPLESS, NORMAN UNIV OF NORTH CAROLINA CHAPEL HILL
18
1/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research 2U54CA156734-06A1 $1,746,493 $104,790 COLON-CARMONA, ADAN UNIVERSITY OF MASSACHUSETTS BOSTON
19
1st International Symposium on Clinical and Experimental Metallodrugs in Medicine: Cancer Chemotherapy 1R13CA200223-01A1 $5,000 $5,000 CONTEL, MARIA BROOKLYN COLLEGE
20
2/2 NCCU-LCCC Partnership in Cancer Research 5U54CA156733-07 $997,277 $79,782 EARP, HENRY UNIV OF NORTH CAROLINA CHAPEL HILL
21
2/2 The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities Research 2U54CA156732-06A1 $1,905,807 $266,813 VISWANATH, KASISOMAYAJULA DANA-FARBER CANCER INST
22
2/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership 2U54CA118623-11 $1,134,399 $34,032 TROY, ROBERTA TUSKEGEE UNIVERSITY
23
2016 Natural Products Gordon Research Conference 1R13CA206198-01 $4,000 $4,000 TAYLOR, RICHARD GORDON RESEARCH CONFERENCES
24
2D and 3D Contrast-enhanced Ultrasound Evaluation of HCC Chemoembolization 1R01CA194307-01A1 $619,717 $619,717 EISENBREY, JOHN THOMAS JEFFERSON UNIVERSITY
25
3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis 1R01CA195443-01A1 $255,216 $127,608 WILLMANN, JUERGEN STANFORD UNIVERSITY
26
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy 5R21CA179362-02 $202,928 $202,928 CUI, ZHENGRONG UNIVERSITY OF TEXAS, AUSTIN
27
A functional genomics approach to determine the mechanism of cellular response to new anti-cancer drugs 1K99CA204602-01 $138,672 $138,672 GILBERT, LUKE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
28
A network platform to connect drug response and prognosis phenotypes for cancers 1R01CA196631-01A1 $395,911 $395,911 LI, HU MAYO CLINIC ROCHESTER
29
A New Small Molecule Targeted Therapeutic for Acute Myeloid Leukemia 1R43CA203172-01 $278,000 $278,000 MU, XUEYAN TEAMEDON INTERNATIONAL, LLC
30
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma 3R44CA159843-03S1 $94,422 $94,422 BALHORN, RODNEY SHAL TECHNOLOGIES, INC.
31
A NOVEL EXTRACELLULAR AND INTRACELLULAR TREATMENT PARADIGM FOR ERADICATING CANCER 5F30CA189435-03 $30,079 $30,079 SOM, AVIK WASHINGTON UNIVERSITY
32
A novel miR-198 replacement therapy for pancreatic cancer 5R01CA183984-02 $473,915 $236,958 YAO, QIZHI BAYLOR COLLEGE OF MEDICINE
33
A novel strategy to overcome resistance in Temozolomide-Refractory Glioblastomas 5R21CA195149-02 $199,553 $199,553 HERGENROTHER, PAUL UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
34
A p53/NFkB-mediated metabolic mechanism for chemotherapy protection 5R01CA183074-03 $335,113 $335,113 YUAN, ZHI-MIN HARVARD SCHOOL OF PUBLIC HEALTH
35
A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy 1R44CA206606-01 $995,814 $995,814 WILDS, DAN CYNVEC, LLC
36
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination with Intravenous Irinotecan in Patients with Recurrent High Grade Gliomas 5R01CA198076-02 $618,770 $618,770 PORTNOW, JANA BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
37
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning 5R01CA199137-02 $524,557 $173,104 AVIS, NANCY WAKE FOREST UNIVERSITY HEALTH SCIENCES
38
A Question Prompt List to Promote Communication in Genomic Medicine 1R21CA201827-01A1 $233,416 $116,708 O'NEILL, SUZANNE GEORGETOWN UNIVERSITY
39
A Suite of Tumor Targeting Peptides for Personalized Therapy of Lung Cancer 5R01CA164447-06 $409,070 $409,070 BROWN, KATHLYNN SRI INTERNATIONAL
40
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer 4R01CA168900-05 $332,000 $166,000 POWELL, DANIEL UNIVERSITY OF PENNSYLVANIA
41
A3AR agonists to prevent chemotherapy-induced painful peripheral neuropathy 4R01CA169519-04 $299,746 $299,746 SALVEMINI, DANIELA SAINT LOUIS UNIVERSITY
42
AAAPT Technology for Improving Chemotherapy 3R43CA183353-01S1 $40,000 $40,000 PANDURANGI, RAGHU SCI-ENGI-MEDCO SOLUTIONS, INC.
43
Aberrant signaling in acute myeloid leukemia 1R01CA204396-01A1 $459,674 $459,674 KENTSIS, ALEX SLOAN-KETTERING INST CAN RESEARCH
44
Abramson Cancer Center Support Grant 2P30CA016520-40 $7,975,543 $558,288 DANG, CHI UNIVERSITY OF PENNSYLVANIA
45
Abramson Cancer Center Support Grant 3P30CA016520-40S1 $31,250 $2,188 DANG, CHI UNIVERSITY OF PENNSYLVANIA
46
Abramson Cancer Center Support Grant 3P30CA016520-40S2 $499,967 $34,998 DANG, CHI UNIVERSITY OF PENNSYLVANIA
47
Abramson Cancer Center Support Grant 3P30CA016520-40S3 $200,000 $14,000 DANG, CHI UNIVERSITY OF PENNSYLVANIA
48
Activating Bax as a therapeutic strategy for lung cancer 4R01CA175003-04 $309,952 $309,952 LI, CHI UNIVERSITY OF LOUISVILLE
49
Addressing Herpesvirus-associated Cancers through the UNC-Malawi Cancer Consortiu 5U54CA190152-03 $699,897 $146,978 GOPAL, SATISH UNIV OF NORTH CAROLINA CHAPEL HILL
50
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment 1R01CA201444-01A1 $413,948 $413,948 MITTELMAN, STEVEN CHILDREN'S HOSPITAL OF LOS ANGELES
Total relevant funding to Chemotherapy for this search: $289,467,872
Showing 1 - 50 of 1045 results
Go to top